APOB and atherosclerosis: To interrogate this possibility one could (1) test individuals who have an atherosclerotic event, despite having a history of normal LDL levels, for the presence of desialylated ApoB100; (2) develop a simple method to quantify the amount of desialylated circulating ApoB100 in order to identify individuals for whom uptake of LDLs by macrophage could lead to atherosclerosis; and (3) develop an effective protocol for inhibiting desialylation of ApoB100 to retard LDL accumulation by macrophage.